NCT00003340View on ClinicalTrials.gov

Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

November 30, 1997

Primary Completion Date

February 29, 2000

Study Completion Date

February 29, 2000

Conditions
Leukemia
Interventions
DRUG

cyclophosphamide

DRUG

topotecan hydrochloride

Trial Locations (1)

21287

Johns Hopkins Oncology Center, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00003340 - Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia | Biotech Hunter | Biotech Hunter